Skip to Content

Garenoxacin Approval Status

Garenoxacin is an investigational broad-spectrum quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.

In August 2006, Schering-Plough Corporation announced the withdrawal of the New Drug Application (NDA) for garenoxacin.

Development Status and FDA Approval Process for Garenoxacin

Feb 13, 2006Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.